SCHEMBL4843853

SCHEMBL4843853

O=P(O)(O)C=Cc1cn(-c2ccccc2)nc1OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.47
PTGS1 P23219 3/20 0.47
PTGES O14684 2/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALPG P10696 1/20 0.37
PTK2B Q14289 1/20 0.37
ADORA1 P30542 1/20 0.37
TSHR P16473 1/20 0.36
PTPRC P08575 1/20 0.36
PTPN1 P18031 1/20 0.36
DUSP1 P28562 1/20 0.36
CDC25A P30304 1/20 0.36
PTPN7 P35236 1/20 0.36
DUSP3 P51452 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4843840 1.00 PTGS2 (0.47) PTGS2PTGS1PTGESKMT2AMEN1
SCHEMBL5411015 0.83 MEN1 (0.57) PTGS2PTGS1KMT2AMEN1ALDH1A1
SCHEMBL5411022 0.83 MEN1 (0.57) PTGS2PTGS1KMT2AMEN1ALDH1A1
SCHEMBL716851 0.81 PTGS2 (0.52) PTGS2PTGS1PTGESKMT2AMEN1
SCHEMBL4850644 0.80 PPARG (0.52) PTPN1
SCHEMBL4850649 0.80 PPARG (0.52) PTPN1
SCHEMBL4843699 0.77 PPARG (0.42) PTGS2PTGS1
SCHEMBL4843713 0.77 PPARG (0.42) PTGS2PTGS1
SCHEMBL4846872 0.75 PDE10A (0.39) KMT2AMEN1ALDH1A1
SCHEMBL4846914 0.75 PDE10A (0.39) KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368578-B2 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-05-06 US disclosed
US-20060135578-A1 Five-membered heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 US disclosed
EP-1541564-A1 FIVE-MEMBERED HETEROCYCLIC COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135578-A1 Five-membered heterocyclic compounds GPR119, OR10J3, CYP11B1 PTGS2 2206/4885PTGS1 740/4885PTGES 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.